ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).

7073 Background: In ENESTnd, NIL has shown superior efficacy vs IM. Here, we report data based on a minimum follow-up of 5 calendar y. Methods: Pts with newly diagnosed CML-CP were randomized to NI...